Novartis AG
NVS
$112.73
$0.850.76%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -11.63% | -1.76% | 20.76% | -68.30% | 381.54% |
| Total Depreciation and Amortization | -85.80% | 4.12% | -3.46% | 176.15% | -215.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 31.86% | 97.34% | -25.23% | 120.47% | -366.91% |
| Change in Net Operating Assets | -130.95% | 1,748.00% | 97.86% | -216.42% | -179.85% |
| Cash from Operations | -33.30% | 28.94% | 115.23% | -11.07% | -52.64% |
| Capital Expenditure | -73.83% | -23.46% | -14.54% | 44.09% | -55.56% |
| Sale of Property, Plant, and Equipment | 4,600.00% | -97.30% | 3,600.00% | -99.39% | 221.57% |
| Cash Acquisitions | -634.48% | 98.24% | -1,266.39% | -3,916.67% | 99.83% |
| Divestitures | 2,242.86% | 126.92% | 31.58% | -1,800.00% | -200.00% |
| Other Investing Activities | -75,233.33% | -100.90% | 185.03% | 73.91% | -204.79% |
| Cash from Investing | -710.96% | 88.34% | -256.73% | 48.92% | 20.43% |
| Total Debt Issued | -100.65% | 20.64% | 149.34% | 123.44% | -- |
| Total Debt Repaid | 92.93% | 47.49% | -3,197.01% | -204.69% | 102.37% |
| Issuance of Common Stock | -100.00% | -80.00% | -- | -- | -- |
| Repurchase of Common Stock | 3.22% | -76.61% | -47.04% | 12.50% | 22.71% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | 53.58% | -- | -- |
| Other Financing Activities | -197.67% | -72.00% | -127.27% | -128.21% | -98.88% |
| Cash from Financing | -684.29% | 88.06% | 38.03% | -750.74% | 27.04% |
| Foreign Exchange rate Adjustments | -278.41% | 617.65% | 73.02% | -178.75% | 196.39% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | 200.00% |
| Net Change in Cash | -137.68% | 464.37% | 60.09% | -497.17% | -35.00% |
